RemeGen's Pioneering RC88 Receives IND Approval from US FDA

FDA Grants IND Approval to RemeGen's RC88 for Phase II Ovarian Cancer Treatment Trials RemeGen's RC88, a novel drug targeting mesothelin,

RC88 DA: RC88 double-acting actuator

rc88 Royalty Core RC88 Billet Headache Rack with Integrated Tail Lights and Dura PODs; Satin Black

rc88 สล็อต RC88 is a novel ADC drug targeting mesothelin , it consists of a recombinant humanized anti-MSLN monoclonal antibody linked to the microtubule inhibitor